Selected publications on current research interest
Langenberg MHG, Witteveen PO, Roodhart J, Lolkema MP, Verheul HM, Mergui-Roelvink M, Brendel E, Kratzschmar J, Loembe B, Nol-Boekel A, Christensen O, Schellens JHM, Voest EE. Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors. Ann Oncol 2011,
David Olmos, Roger A’Hern, Silvia Marsoni, Josep Tabernero, Carlos Gomez-Roca, Jaap Verweij, Emile E. Voest, Patrick Schöffski, Joo Ern Ang, Nicolas Penel, Jan H. Schellens, Luca Gianni, Andre T. Brunetto, Jeff Evans, Richard Wilson, Cristiana Sessa, Ruth Plummer, Rafael Morales, Jean-Charles Soria, Stan B. Kaye, On behalf of the European Drug Development Network (EDDN). Patient selection for oncology phase 1 trials- a multi-institutional study of prognostic factors. J Clin Oncol 2011
Ron C.J. Schackmann, Miranda van Amersfoort, Judith H.I. Haarhuis, Eva J. Vlug, Vincent A.
Halim, Jeanine M.L. Roodhart, Joost S. Vermaat, Emile E. Voest, Petra van der Groep, Paul J. van Diest, Jos Jonkers and Patrick W.B. Derksen. Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistance. Nature Cell Biology 2011
Walraven M, Witteveen PO, Lolkema MP, van Hillegersberg R, Voest EE, Verheul RM. Antiangiogenic tyrosine kinase inhibition related gastrointestinal perforations: a case report and literature review. Angiogenesis 2010 Dec 29. [Epub ahead of print]
E van Rooijen, K Santhakumar, I Logister, E Voest, S Schulte-Merker1, R Giles and F van Eeden. A zebrafish model for VHL and hypoxia signaling. Mol Cell Biol 2010, in press
Lens SMA, Voest EE, Medema RH. Shared and separate functions of Polo-like and Aurora kinases in cancer. Nat Rev Cancer, 2010;10:825-841
Witteveen PO, van der Mijn KJ, Los M, Kronemeijer RH, Groenewegen G, Voest EE.
Phase 1/2 study of atrasentan combined with pegylated liposomal Doxorubicin in platinum-resistant recurrent ovarian cancer. Neoplasia. 2010;12:941-5.
Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer. 2010 Oct 11;10:545.
Boss DS, Witteveen PO, van der Sar J, Lolkema MP, Voest EE, Stockman PK, Ataman O, Wilson D, Das S, Schellens JH. Clinical evaluation of AZD1152, an i.v. inhibitor of Aurora B kinase, in patients with solid malignant tumors. Ann Oncol. 2010; ahead op print
Wessels H, de Graeff A, Wynia K, de Heus M, Kruitwagen CL, Teunissen SC, Voest EE. Are health care professionals able to judge cancer patients' health care preferences correctly? A cross-sectional study. BMC Health Serv Res. 2010 Jul 8;10:198
Wessels H, de Graeff A, Wynia K, de Heus M, Kruitwagen CL, Woltjer GT, Teunissen SC, Voest EE. Gender-related needs and preferences in cancer care indicate the need for an individualized approach to cancer patients. Oncologist. 2010;15(6):648-55.
Wessels H, de Graeff A, Groenewegen G, Wynia K, de Heus M, Vos JB, Tjia P, Kruitwagen CL, Teunissen SC, Voest EE. Impact of integration of clinical and outpatient units on cancer patient satisfaction. Int J Qual Health Care. 2010 Aug 3.
Kroeze SG, Vermaat JS, van Brussel A, van Melick HH, Voest EE, Jonges TG, van Diest PJ, Hinrichs J, Bosch JL, Jans JJ. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients. Eur J Cancer, 2010; Aug 13,
Daenen LG, Roodhart J, Shaked Y, Voest EE. Vascular Disrupting Agents (VDAs) in Anticancer Therapy. Curr Clin Pharmacol 2010, 5: 178-185
Ellen van Rooijen, Emile E. Voest, Ive Logister, Jeroen Bussmann, Jeroen Korving, Fredericus J. van Eeden, Rachel H. Giles and Stefan Schulte-Merker von Hippel-Lindau tumor suppressor mutants faithfully model pathological hypoxia-driven angiogenesis and vascular retinopathies in zebrafish
Morgan Nordstrom-O’Brien, Robert B. van der Luijt, Ans M. van den Ouweland, Martijn P. Lolkema, Emile E. Voest, and Rachel H. Giles. Genetic Analysis of von Hippel-Lindau Disease. Human Mutations, in press
Overkleeft EN, Goldschmeding R, van Reekum F, Voest EE, Verheul HM. Nephrotic syndrome caused by the angiogenesis inhibitor sorafenib. Ann Oncol 2009; Nov 4.
Laura G. Daenen, Yuval Shaked, Shan Man, Ping Xu, Emile E. Voest, Robert M. Hoffman, David Chaplin, and Robert S. Kerbel. Low-Dose Metronomic Cyclophosphamide Combined with Vascular Disrupting Therapy Induces Potent Anti-Tumor Activity in Preclinical Human Tumor Xenograft Models. Mol Cancer Ther 2009;8:2872-2881
Lankheet AG, Hillebrand MJ, Langenberg MH, Rosing H, Huitema AD, Voest EE, Schellens J, Beijnen JH. A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectometry. J Chromatogr B Analyt Technol Biomed Life Sci 2009; 877:3625-3630
Yuval Shaked, Terence Tang, Jill Woloszynek, Laura G. Daenen, Shan Man, Ping Xu, Shi-Rong Cai, Jeffrey M. Arbeit, Emile E Voest, David Chaplin, Jon Smythe, Adrian Harris, Paul Nathan, Ian Judson, Gordon Rustin, Francesco Bertolini, Daniel C Link, Robert S. Kerbel. Contribution of G-CSF to the acute mobilization of endothelial precursor cells by vascular disrupting agents. Cancer Research 2009;69: 7524-7528
Shaked Y and Voest EE. Bone marrow derived cells in angiogenesis and growth: are they the good, the bad or the evil ? BBA Reviews on Cancer 2009; 1796: 1-4
Engwegen JY, Mehra N, Haanen JB, Schellens JH, Voest EE, Beijnen JH. Identification of two new serum profiles for renal carcinoma. Oncol Reports. 2009; 22: 401-408
Marlies H.G. Langenberg, Carla M.L. van Herpen, Johann De Bono,
Jan H.M. Schellens, Clemens Unger, Klaas Hoekman, Hubert E. Blum,
Walter Fiedler, Joachim Drevs, Florence Le Maulf, Anitra Fielding, Jane Robertson, and Emile E. Voest. Effective strategies for management of hypertension following VEGF signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of cediranib in patients with advanced solid tumors. J Clin Oncol 2009, in press
Linsen SE, de Wit E, Janssens G, Heater S, Chapman L, Parkin RK, Fritz B, WymanSK, de Bruijn E, Voest EE, Kuersten S, Tewari M, Cuppen E. Limitations and possibilities of small RNA digital gene expression profiling. Nature Methods 2009; 6:474-476
Homs MY, Voest EE, Siersema PD. Emerging drugs for esophageal cancer Expert Opin Emerg Drugs. 2009; 14:329-339
H. Wessels, A. de Graeff, K. Wynia, HJ Sixma, M. de Heus, M, Schipper, GT Woltjer, Teunissen SC, EE Voest Medical oncology patients' preferences with regard to health care: development of a patient-driven questionnaire. Ann Oncol 2009; 20:1708-1713
Jeanine M Roodhart, Marlies Langenberg, Laura G Daenen, Emile Voest. Translating preclincal findings of (endothelial) progenitor cell mobilization into the clinic; from bedside to bench and back. BBA - Reviews on Cancer, 2009; 1796 (1): 41-49
Oostendorp RL, Witteveen PO, Schwartz B, Vainchtein LD, SchotM, Nol A, Rosing H, Beijnen JH, Voest EE, Schellens JH. Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors. Invest New Drugs, in press.
Nijkamp MW, van der Bilt JD, de Bruijn MT, Molenaar IQ, Voest EE, van Diest PJ, Kranenburg O, Borel Rinkes IH. Accelerated Perinecrotic Outgrowth of Colorectal Liver Metastases Following Radiofrequency Ablation is a Hypoxia-Driven Phenomenon. Ann Surg 2009; 249: 814-823
Ellen van Rooijen1-2, Emile E. Voest1, Ive Logister1-2, Jeroen Korving2, Thorsten Schwerte3, Stefan Schulte-Merker2, Rachel H. Giles1* and Freek J. van Eeden2Zebrafish mutants in the von Hippel-Lindau (VHL) tumor suppressor display a hypoxic response and recapitulate key aspects of Chuvash polycythemia, Blood 2009; 113: 6449-6460
Oostendorp RL, Loftiss J, Goel S, Smith DA, Dar MM, Witteveen PO, Cohen RB, Lewis LD, Kurian S, Patnaik A, Rosing H, Beijnen JH, Voest EE, Burris H, J. Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors. Int J Clin Pharmacol Ther. 2009; 47:195-206.
Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJ, Schrama JG, Erdkamp FL, Vos AH, van Groeningen CJ, Sinnige HA, Richel DJ, Voest EE, Dijkstra JR, Vink-Börger ME, Antonini NF, Mol L, van Krieken JH, Dalesio O, Punt CJ. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360:563-572
Yuval Shaked, Erik Henke, Jeanine Roodhart, Patrizia Mancuso, Marlies Langenberg, Marco Colleoni, Laura G. Daenen, Shan Man, Ping Xu, Urban Emmenegger, Terence Tang, Zhenping Zhu, Larry Witte, Robert M. Strieter, Francesco Bertolini, Emile Voest, Robert Benezra and Robert S. Kerbel. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008; 14: 263-73
Roodhart JM, Langenberg MH, Witteveen E, Voest EE. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol 2008; 3:132-143
Nieboer P, de Vries EG, Mulder NH, Rodenhuis S, Bontenbal M, van der Wall E, van Hoesel QG, Smit WM, Hupperets P, Voest EE, Nooij MA, Boezen HM, van der Graaf WT. Factors influencing catheter-related infections in the Dutch multicenter study on high-dose chemotherapy followed by peripheral SCT in high-risk breast cancer patients. Bone Marrow Transplant. 2008 Jul 14.
SA Veltkamp, P.O Witteveen, A Capriati, S Bini, M Voogel-Fuchs, R Kronemeyer, JH Beijnen, EE Voest, JHM Schellens. Clinical and pharmacological study of the novel prodrug MEN 4901/T-0128 in patients with solid tumors. Clin Cancer Res 2008, 14: 7535-7544
N. Snoeren, E.E.Voest, R. van Hillegersberg. Surgery vs surgery and chemotherapy for colorectal liver metastases. Lancet 2008; 372: 202-3
Greijer AE, Delis-van Diemen PM, Fijneman RJ, Giles RH, Voest EE, van Hinsberg VW, Meijer GA. Presence of HIF-1 and related genes in normal mucosa, adenomas and carcinomas of the colorectum. Virchows Arch. 2008; 452:535-544
D.A. Mans, E.E. Voest, R.H. Giles. All along the watchtower: Is the cilium a tumor suppressor organelle? Biochim Biophys Acta. 2008 Feb 26; [Epub ahead of print]
Mans DA, Lolkema MP, van Beest M, Daenen LG, Voest EE, Giles R. Mobility of the von Hippel-Lindau tumour suppressor protein is regulated by kinesin-2. Exp Cell Res 2008, 314:1229-1236
Ellen van Rooijen, Rachel H. Giles, Emile E. Voest, Carina van Rooijen, Stefan Schulte-
Merker and Freek J. van Eeden. LRRC50, a conserved ciliary protein implicated in polycystic kidney disease. J Am Soc Nephrol 2008, 19:1128-1138
Lolkema MP, Mans DA, Ulfman LH, Volpi S, Voest EE, Giles RH. Allele-specific regulation of primary cilia function by the von Hippel-Lindau tumor suppressor. Eur J Hum Genet. 2008;16:73-78
Buijs C, Rodenhuis S, Seynaeve CM, van Hoesel QG, van der Wall E, Smit WJ, Nooij MA, Voest E, Hupperets P, Ten Vergert EM, van Tinteren H, Willemse PH, Mourits MJ, Aaronson NK, Post WJ, de Vries EG. Prospective study of long-term impact of adjuvant high-dose and conventional-dose chemotherapy on health-related quality of life. J Clin Oncol 2007;24:5403-5439
Henk M.W. Verheul, Martijn P.J. Lolkema, David Z. Qian, Yvonne H.A. Hilkes, Eleni Liapi, Jan-Willem N. Akkerman, Roberto Pili and Emile E. Voest. Platelets take up the monoclonal antibody bevacizumab. Clin Cancer Res, 2007; sept 12
Rademaker-Lakhai JM, Beerepoot LV, Mehra N, Radema SA, van Maanen R, Vermaat JS, Witteveen PO, Visseren-Grul CM, Musib L, Enas N, van Hal G, Beijen JH, Schellens JH, Voest EE. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2007;13:4474-4481
Niven Mehra, Maarten Penning, Jolanda Maas, Nancy van Daal, Rachel H Giles and Emile E Voest. Circulating mitochondrial nucleic acids have prognostic value for survival in advanced prostate cancer patients. Clin Cancer Res 2007;13:421-426
M.Los, J. Roodhart, P.O. Witteveen, E.E. Voest. Target Practice: Lessons from Phase III Trials with Bevacizumab and Vatalanib in the Treatment of Advanced Colorectal Cancer. The Oncologist 2007,12:443-450
Niven Mehra, Maarten Penning, Jolanda Maas, Laurens V Beerepoot, Nancy van Daal, Carla H van Gils, Rachel H Giles, and Emile E Voest. Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases. Clin Cancer Res 2006;12:4859-4866.
Laurens V. Beerepoot, Sandra A. Radema, Els O. Witteveen, Tawnie Thomas, Catherine Wheeler, Sanford Kempin, and Emile E. Voest. Phase I clinical evaluation of weekly administration of the novel vascular-targeting agent, ZD6126, in patients with solid tumors.
J Clin Oncol 2006;24:1491--1498
Rachel H. Giles 1, Martijn P. Lolkema 1, Cristel M. Snijckers 1, Anita S. Jorna 1, Petra van der Groep 2, Moniek van Beest 1, Mascha van Noort 3, Roel Goldschmeding 2, Paul J. van Diest 2, Hans Clevers 4, Emile E. Voest 1. Interplay between VHL/HIF1alpha and Wnt/beta-catenin pathways during colorectal tumorigenesis. Oncogene, 2006;25:3065-70
O. Kranenburg, M.F.Gebbink, E.E. Voest. Stimulation of angiogenesis by Ras proteins. Biochimica et Biophysica Acta (BBA), Reviews on Cancer, 2004;1654:23-37 L.V.Beerepoot, P.O. Witteveen, G.Groenewegen, W.E.Fogler, B.K.L.Sim, C.Sidor, E.Phillips, B.A.Zonnenberg, F.Schramel, M.F.B.G.Gebbink,
E.E.Voest Pharmacologic and Long-term safety report of a phase I trial applying an antiangiogenic schedule of recombinant human Angiostatin in patients with advanced cancer by twice-daily subcutaneous injection. Clin Cancer Res 2003, 9:4025-4033
Los M, Kerckhaert OAJ, Zewald R, Ploos van Amstel HK, Voest EE. Somatic mutations of the VHL tumor suppressor gene are absent in tumor-derived endothelial cells of von Hippel-Lindau patients. J Natl Cancer Inst 2000; 92: 1688-1689